Reviewing Detection of Peptidic Drugs in Sports Doping Control

The landscape of performance-enhancing drugs in sports is constantly evolving, with peptidic drugs and their analogs becoming increasingly prevalent due to their diverse physiological effects. These substances, ranging from growth factors to metabolic regulators, pose significant challenges for anti-doping efforts. This review addresses the critical need to summarize the current analytical strategies and identify future directions for detecting these complex compounds in sports doping.

The review highlighted that while significant advancements have been made in analytical techniques, the detection of peptidic drugs remains highly challenging due to factors such as their low concentrations, short half-lives, and structural similarity to endogenous peptides. It emphasized that LC-MS/MS methods have shown improved sensitivity, often achieving detection limits in the picogram per milliliter range, crucial for identifying trace amounts. The most important finding is the continuous "cat-and-mouse" game between drug developers and anti-doping agencies, necessitating constant innovation to keep pace with new, often designer, peptidic substances. The review noted that detection windows for many peptides are often limited to 24-72 hours, making targeted in-competition testing critical. Furthermore, the complexity of distinguishing exogenous administration from natural physiological variations presents a persistent hurdle, requiring sophisticated confirmatory assays and longitudinal profiling.